Rigel Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Rigel Pharmaceuticals, Inc. Overview

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. 2025 was an excellent year for Rigel, marked by strong commercial execution with record net product sales, significant financial progress including continued profitability and generation of $77 million in cash, and meaningful clinical advancement of R289 in lower-risk MDS.

Strategic Profile

Founded in 1996 and based in South San Francisco, California, Rigel develops and commercializes targeted small-molecule and oral therapies that address serious blood and cancer conditions where treatment needs remain. Major products include Tavalisse, an oral spleen tyrosine kinase inhibitor for chronic immune thrombocytopenia, Rezlidhia for relapsed or refractory acute myeloid leukemia with IDH1 mutations, and Gavreto for metastatic RET fusion-positive non-small cell lung cancer and advanced thyroid cancers.

Competitive Landscape

Rigel competes in the hematology-oncology drug space against larger pharmaceutical companies including Eli Lilly (collaborator on ocadusertib), as well as other biotech firms developing targeted therapies for blood disorders and cancer. Key differentiation comes from Rigel's focused portfolio of three approved products with distinct mechanisms and its early-stage pipeline. Partnership collaborations with companies like Grifols, Kissei Pharmaceutical, and others generate contract revenues while reducing development costs.

Industry Context

Rigel Pharmaceuticals, Inc. operates in Biopharmaceuticals / Oncology & Hematology.

Key facts

Founded: 1996 · Headquarters: South San Francisco, US · Employees: 162 · Revenue: $294.3M · Market cap: $634.2M